Collegium Pharmaceutical
COLL
223 hedge funds and large institutions have $1.06B invested in Collegium Pharmaceutical in 2025 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 89 increasing their positions, 83 reducing their positions, and 34 closing their positions.
2,088% more call options, than puts
Call options by funds: $372K | Put options by funds: $17K
7% more repeat investments, than reductions
Existing positions increased: 89 | Existing positions reduced: 83
4% less capital invested
Capital invested by funds: $1.1B → $1.06B (-$40.4M)
5.51% less ownership
Funds ownership: 116.59% → 111.08% (-5.5%)
8% less funds holding
Funds holding: 242 → 223 (-19)
41% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 34
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JGC
J. Goldman & Co
New York
|
+$6.94M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$4.5M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$4.27M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.9M |
| 5 |
BAM
Ballast Asset Management
Dallas,
Texas
|
+$2.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$12.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$7.7M |
| 3 |
QC
Quantedge Capital
Singapore
|
-$7.1M |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
-$5.87M |
| 5 |
BlackRock
New York
|
-$3.21M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$8.42K | -282 | Closed |
|
|
PC
252
Promethos Capital
Boston,
Massachusetts
| – | -$4.48K | -150 | Closed |
|
|
HCP
253
Hexagon Capital Partners
Rogers,
Arkansas
| – | -$2.92K | -98 | Closed |
|
|
FDCDDQ
254
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| – | -$1.37K | -46 | Closed |
|
|
SPIA
255
Steward Partners Investment Advisory
New York
| – | -$925 | -31 | Closed |
|
|
SW
256
SVB Wealth
Boston,
Massachusetts
| – | -$657 | -22 | Closed |
|
|
TFA
257
Toth Financial Advisory
Leesburg,
Virginia
| – | -$329 | -11 | Closed |
|
|
CAL
258
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$57 | +2 | New |
|
COLL Hedge Fund Activity: Q2 2025 in Review
223 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2025, worth a combined $1.06B — down 3.7% from $1.1B a quarter earlier.
Sellers outnumbered buyers: 34 funds closed out of COLL and 20 opened new positions — a net loss of 14 holders — while 83 trimmed existing stakes and 89 added.
The largest buyer was J. Goldman & Co, opening a new position worth an estimated $6.94M. The largest seller was Millennium Management, cutting an estimated $12.1M.
- 223 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2025, down from 242 in Q1 2025.
- Funds reported $1.06B of Collegium Pharmaceutical stock for Q2 2025, down 3.7% quarter-over-quarter.
- 20 funds opened new Collegium Pharmaceutical positions in Q2 2025 and 34 closed out, a net change of -14 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2025 was J. Goldman & Co, an estimated $6.94M added.
- The largest Collegium Pharmaceutical seller in Q2 2025 was Millennium Management, an estimated $12.1M sold.
Based on aggregated 13F filings for Q2 2025.